ALTAMIRA THERAPEUTICS
Altamira Therapeutics is dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus, and restore balance. Altamira Therapeutics is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo. They have additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.
ALTAMIRA THERAPEUTICS
Industry:
Health Care Pharmaceutical Therapeutics
Founded:
2003-04-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.altamiratherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+41 61 201 13 50
Total Funding:
122.54 M USD
Technology used in webpage:
Euro SPF Amazon IPv6 Microsoft Exchange Online Cloudflare JS Office 365 Mail CDN JS AJAX Libraries API Microsoft Azure DNS
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Arsenal Medical
Arsenal Medical develops novel products that improve local therapy for injuries and diseases.
Cheplapharm Arzneimittel
Cheplapharm is a pharmaceutical company that offers branded drugs, medical products, supplements, and cosmetics.
Closed Loop Medicine
Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians
electroCore
ElectroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders.
Enterprise Therapeutics
A UK-based developer of drugs to treat respiratory diseases
InflaRx
InflaRx develops new therapeutics in the field of acute and chronic inflammation.
Mithra Pharmaceuticals SA
Mithra Pharmaceuticals SA specializes in the development of women's health care products.
ReCor Medical
ReCor Medical has developed a unique therapeutic non-focused ultrasound system
Current Employees Featured
Marcel Gremaud Chief Financial Officer @ Altamira Therapeutics
Chief Financial Officer
Samuel A. Wickline Chief Scientific Officer @ Altamira Therapeutics
Chief Scientific Officer
2021-06-01
James Healy Director @ Altamira Therapeutics
Director
Oliver Kubli Director @ Altamira Therapeutics
Director
Wolfgang Arnold Director @ Altamira Therapeutics
Director
Alain Munoz Director @ Altamira Therapeutics
Director
Thomas Meyer CEO and Founder @ Altamira Therapeutics
CEO and Founder
2003-04-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-06-03 | Trasir Therapeutics | Trasir Therapeutics acquired by Altamira Therapeutics | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Altamira Therapeutics
Sofinnova Partners
Sofinnova Partners investment in Series C - Altamira Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series C - Altamira Therapeutics
ZKB Pharma Vision Fund
ZKB Pharma Vision Fund investment in Series B - Altamira Therapeutics
Idinvest Partners
Idinvest Partners investment in Series B - Altamira Therapeutics
Lacuna
Lacuna investment in Series B - Altamira Therapeutics
Idinvest Partners
Idinvest Partners investment in Series A - Altamira Therapeutics
Official Site Inspections
http://www.altamiratherapeutics.com Semrush global rank: 5.27 M Semrush visits lastest month: 1.46 K
- Host name: lx20.hoststar.hosting
- IP address: 168.119.41.54
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Altamira Therapeutics"
Altamira Therapeutics Provides Business Update and First Half …
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ET Continued progress within core activities in RNA delivery, supported by …See details»
Altamira Therapeutics Provides Investor and Business Update
HAMILTON, BERMUDA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ET Partial spin-off of Bentrio® business …See details»
Leadership Team - Altamira Therapeutics
Dr. Pañeda has over 15 years of experience in drug development. She spent 7 years as R&D Manager at Sylentis S.A., a clinical stage RNAi biopharma company and most recently, she served as Director of Development at Limm …See details»
Altamira Therapeutics Company Description - Stock Analysis
Dec 26, 2024 Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies …See details»
Altamira Therapeutics
Dec 20, 2024 Altamira Therapeutics was founded in 2017 by a team of leading scientists and healthcare entrepreneurs. The team had a shared vision to make a difference in patients’ lives …See details»
CYTOF - Altamira Therapeutics Ltd. | Company Profile | OTC Markets
Dec 20, 2024 altamiratherapeutics.com (441) 295-5950. hear@altamiratherapeutics.com. Business Description. Altamira Therapeutics (CYTO) is developing and supplying peptide …See details»
Altamira Therapeutics - LinkedIn
Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore™ / SemaPhore™ delivery platforms).See details»
Altamira Therapeutics | LinkedIn
Altamira Therapeutics | 1.342 Follower:innen auf LinkedIn. Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets. | Altamira Therapeutics is …See details»
Altamira Therapeutics AG – Swiss Biotech
Altamira Therapeutics is developing and supplying peptide-based nanoparticles for efficient RNA delivery to extrahepatic tissues. Our versatile OligoPhore™ and SemaPhore™ platforms are …See details»
Altamira Therapeutics’ CEO Interviewed by Proactive Investors to ...
HAMILTON, BERMUDA -- August 3, 2022 -- Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important …See details»
Altamira Therapeutics - RNA Therapeutics
In the US in 2014, approximately 1.3 million adults suffered from RA (Hunter et al., 2017) and according to the World Health Organization (WHO), the autoimmune disease affects globally …See details»
Altamira Therapeutics - Overview, News & Similar companies
Dec 28, 2023 Altamira Therapeutics contact info: Phone number: (302) 200-8095 Website: www.altamiratherapeutics.com What does Altamira Therapeutics do? Altamira Therapeutics is …See details»
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results …
May 12, 2023 Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. To …See details»
Altamira Therapeutics Provides Business Update and First Half …
HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration …See details»
Altamira Therapeutics to Develop Novel Generation of …
Jul 25, 2022 RA is a chronic inflammatory condition causing joint swelling and pain which may also affect other areas, including the skin, eyes, brain, and cardiovascular system. In the US, …See details»
Altamira Therapeutics Ltd. to Transition from Nasdaq to OTCQB …
Dec 20, 2024 Altamira Therapeutics will trade on OTCQB after Nasdaq delisting due to non-compliance with minimum bid price rules. Quiver AI Summary. Altamira Therapeutics Ltd. …See details»
Altamira Therapeutics Announces Successful Nanoparticle-Based …
2 days ago Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA deliveryCircular mRNA significantly …See details»
Investors & Media - Altamira Therapeutics
Apr 10, 2023 Published meta-analysis shows statistically significant improvement in dizziness handicap for betahistine treatment over standard of care procedure alone in patients suffering …See details»
Altamira Therapeutics Announces Successful ... - Markets Insider
2 days ago Hear@altamiratherapeutics.com. Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. SHARE THIS POST. FACEBOOK. …See details»
Investors & Media - ir.altamiratherapeutics.com
2 days ago Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA delivery Circular mRNA significantly …See details»